This paper’s objective was to assess the age and gender differences of clients accessing mobile HIV counselling and testing (HCT) compared with clients accessing facility-based testing, and to determine the difference in HIV prevalence and baseline CD4 counts. A prospective observational cross-sectional study was conducted of three different HIV testing services in Cape Town. The researchers compared data on age, sex, HIV status and CD4 counts collected between August and December 2008 from a mobile testing service (known as the Tutu Tester), a primary health care clinic, and a district hospital. A total of 3,820 individuals were tested. Of the HIV-infected individuals from the mobile service, 75% had a CD4 count higher than 350 cells/µl compared with 48% and 32% respectively at the clinic and hospital. Age- and sex-adjusted risk for HIV positivity was 3.5 and 4.9 times higher in the clinic-based and hospital-based services compared with the mobile service. The authors conclude that mobile services are accessed by a different population compared with facility-based services. Mobile service clients were more likely to be male and less likely to be HIV-positive, and those infected presented with earlier disease.
Equity and HIV/AIDS
Kaposi's sarcoma (KS), an HIV-related cancer, is neglected in HIV and AIDS services in Africa, according to Medicines Sans Frontiers (MSF). How to administer chemotherapy at a small rural clinic is just one of the many difficulties faced by health workers treating patients with KS at 10 health facilities run by Medicines Sans Frontiers (MSF) in the Chiradzulu district of southern Malawi. Other challenges are the lack of infrastructure and safety equipment for injection-driven chemotherapy, poor case management and problematic drug supplies. MSF research, which was presented at the meeting of the Rural Doctors Association of Southern Africa (RuDASA) in Swaziland in August, found that about 7% of 11,100 ARV patients surveyed in Thyolo district had KS. Dr Francois Venter, head of the Southern African HIV Clinicians Society, said that the incidence rate in Africa is still lower than developed countries, but because of the sheer number of patients and because they present so late for treatment, KS remains an ever-present danger. He noted that the cancer was difficult to manage even in better-resourced healthcare settings like academic hospitals. MSF is now planning to train palliative care teams to handle difficult cases, and to develop a protocol to guide health workers regarding the special needs of KS patients, including how to dress lesions.
Self-tests for HIV in South Africa are currently unregulated. Gaps in law and policy have created a legal loophole where such tests could effectively be sold in supermarkets, but not in pharmacies. At the same time, South Africa lacks an effective regulating mechanism for diagnostic tests, which brings the quality and reliability of all self- tests into question. The authors argue for greater access to, and availability of, quality HIV self-tests, despite drawbacks like increased risk of unmanaged anxiety with potential for suicide if a positive result is given, lack of counselling and possible family coercion into testing. They argue that self-testing will lead to earlier diagnosis of HIV status and earlier enrolment into treatment, and decrease the costs associated with traditional voluntary counselling and testing, and allay fears about stigma and confidentiality when testing in public facilities.
This study investigated the factors associated with uptake of antiretroviral therapy (ART) through a primary healthcare system in rural South Africa. Detailed demographic, HIV surveillance and geographic information system (GIS) data was used to estimate the proportion of HIV positive adults accessing antiretroviral treatment within northern KwaZulu-Natal, South Africa in the period from initiation of antiretroviral roll-out until the end of 2008. Demographic, spatial and socioeconomic factors influencing the likelihood of individuals accessing antiretroviral treatment were explored using multivariable analysis. Mean uptake of ART among HIV positive resident adults was found to be 21.0%. Uptake among HIV positive men (19.2%) was slightly lower than women (21.8%). An individual's likelihood of accessing ART was not associated with level of education, household assets or urban/rural locale. ART uptake was strongly negatively associated with distance from the nearest primary healthcare facility. Despite concerns about the equitable nature of antiretroviral treatment rollout, the study identified very few differences in ART uptake across a range of socio-demographic variables in a rural South African population. However, even when socio-demographic factors were taken into account, individuals living further away from primary healthcare clinics were still significantly less likely to be accessing ART.
Recent guidelines recommend that all HIV-infected women should receive highly active antiretroviral therapy throughout pregnancy and lactation, irrespective of whether or not they need it for their own health. This strategy for prevention of mother-to-child transmission (PMTCT) of HIV is more effective than the well-established use of single-dose nevirapine, but it is also a more costly alternative. In this economic evaluation, the researchers used a decision model to combine the best available clinical evidence with cost, epidemiological and behavioural data from Northern Tanzania. It found that a highly active antiretroviral therapy-based PMTCT Plus regimen is more cost effective than the current Tanzanian standard of care with single-dose nevirapine. Although PMTCT Plus is roughly 40% more expensive per pregnant woman than single-dose nevirapine, the expected health benefits are 5.2 times greater. The incremental cost effectiveness ratio of the PMTCT Plus intervention is calculated to be US$4,062 per child infection averted and $162 per disability-adjusted life year.
The results of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 tenofovir gel trial showed a 39% reduction in new HIV infections, and are considered a critical first step to getting an effective HIV prevention method for women. Much more research still needs to be done, CAPRISA cautions. As a follow-up to the CAPRISA 004 tenofovir gel trial, the global microbicide community has yet to define the quickest route to getting tenofovir gel to the public. There was consensus among the community members that confirmatory trials and implementation studies are urgently needed. However, a key challenge is insufficient funding to undertake the critical next steps. The proposed research is expected to cost approximately US$100 million over three years, of which only $58 million has been committed so far.
A global shortage of funds for the fight against HIV means universal access to prevention, treatment and care is unlikely unless HIV programmes get better value for their investments, according to this report. It argues that there is a need to ‘enhance the impact of current investments by improving the efficiency, effectiveness and quality of programmes, strengthening links between programmes, and building systems for a sustainable response. Although 5.25 million people accessed life-prolonging antiretroviral medication in 2009 - up 1.2 million from 2008 - the report notes that funding shortages, limited human resources, weak procurement and supply management systems for HIV drugs and diagnostics, and other bottlenecks continued to hamper the scale-up of treatment. An estimated 53% of pregnant women worldwide in need of prevention of mother-to-child transmission services received them in 2009, but only 28% HIV-positive children received treatment in 2009, compared to 36% for adults, and just 15% of children born to HIV-positive mothers were given appropriate infant diagnostics.
The notion that concurrent sexual partnerships are especially common in sub-Saharan Africa and explain the region's high HIV prevalence is accepted by many as conventional wisdom. This paper’s findings contradict that belief. The paper evaluated the quantitative and qualitative evidence offered by the principal proponents of the concurrency hypothesis and analysed the mathematical model they use to establish the plausibility of the hypothesis. It found that research seeking to establish a statistical correlation between concurrency and HIV prevalence either finds no correlation or has important limitations. Furthermore, in order to simulate rapid spread of HIV, mathematical models require unrealistic assumptions about frequency of sexual contact, gender symmetry, levels of concurrency, and per-act transmission rates. The paper considers qualitative evidence offered by proponents of the hypothesis as irrelevant since, among other reasons, there is no comparison of Africa with other regions. It concludes that promoters of the concurrency hypothesis have failed to establish that concurrency is unusually prevalent in Africa or that the kinds of concurrent partnerships found in Africa produce more rapid spread of HIV than other forms of sexual behaviour. Policy makers should turn attention to drivers of African HIV epidemics that are policy sensitive and for which there is substantial epidemiological evidence.
This study looked at HIV prevalence in the higher education sector in South Africa. It reported both quantitative and qualitative data. Out of a total of 29,856 eligible participants available at testing venues, 79,1% participated fully by completing questionnaires and providing specimens. Because of a substantial amount of missing data in 230 questionnaires, the final database consisted of 23,375 individuals made up of 17,062 students, 1,880 academic staff and 4,433 administrative and service staff. The mean HIV prevalence for students was 3,4%. HIV was significantly more common among men (6,5%) and women (12,1%) who reported symptoms of a sexuallty transmitted infection (STI) in the last year compared to men (2,5%) and women (6%) who did not report an STI. First-year students appeared to lack the required experience to make good, risk-aware decisions, especially regarding sexual liaisons and the use of alcohol. Qualitative data pointed to underlying causes of HIV transmission on campus as including reported transactional sex, intergenerational sex (a young woman with an older wealthier man), poor campus leadership on HIV and AIDS, limited uptake of voluntary testing and counseling services, poor levels of security on campus and stigma surrounding the disease.
The objective of this study was to determine the incidence of loss to follow-up in a treatment programme for people living with human immunodeficiency virus (HIV) infection in Kenya and to investigate how loss to follow-up is affected by gender. Between November 2001 and November 2007, 50,275 HIV-positive individuals aged 14 years and older (69% female) were enrolled in the study. An individual was lost to follow-up when absent from the HIV treatment clinic for more than three months if on combination antiretroviral therapy (cART) or for more than six months if not. Overall, 8% of individuals attended no follow-up visits, and 54% of them were lost to follow-up. The overall incidence of loss to follow-up was high, at 25.1 per 100 persons annually. Among the 92% who attended at least one follow-up visit, the incidence of loss to follow-up before and after starting cART was respectively 27.2 and 14.0 per 100 persons annually. Baseline factors associated with loss to follow-up included younger age, a long travel time to the clinic, patient disclosure of positive HIV status, high CD4+ lymphocyte count, advanced-stage HIV disease, and rural clinic location. Men were at an increased risk overall and before and after starting cART. The study concluded that interventions designed separately for men and women could improve retention.